Company intelligence / Profile preview

Di-AcetylM

Ownership: Private
Development stage: Other

Overview

Di-AcetylM is a biotechnology company focused on developing novel therapeutic solutions for opioid use disorder and chronic pain management. The company utilizes a proprietary prodrug technology platform designed to improve the safety and efficacy profiles of existing opioid-based treatments. By engineering molecules that require specific metabolic activation, Di-AcetylM aims to reduce the potential for abuse and overdose while maintaining therapeutic benefits. Their lead programs are currently in the pre-clinical stage, targeting the opioid receptor system with enhanced pharmacokinetic control.

Therapeutic areas: PsychiatryNeurology
Modalities: Small molecule
Industry: Biotech

Beyond the preview

Go deeper on Di-AcetylM.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Di-AcetylM.

Explore the full profile